ATC Group: L04AA06 Mycophenolic acid

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L04AA06 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L04 Immunosuppressants
3 L04A Immunosuppressants
4 L04AA Selective immunosuppressants
5 L04AA06 Mycophenolic acid

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Code Route Amount Notes
ORAL Oral 2 g
PAREN Parenteral 2 g

Active ingredients in L04AA06

Active Ingredient

Mycophenolate mofetil is the 2-morpholinoethyl ester of mycophenolic acid (MPA). MPA is a potent, selective, uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase, and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA.

Mycophenolic acid is a potent, selective, uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase, and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA. Mycophenolic acid has more potent cytostatic effects on lymphocytes than on other cells and is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in adult patients receiving allogeneic renal transplants.

Related product monographs

Document Type Information Source  
 CELLCEPT Capsules, hard MPI, EU: SmPC European Medicines Agency (EU)
 CELLCEPT Powder for concentrate for solution for infusion MPI, EU: SmPC European Medicines Agency (EU)
 CEPTAVA Gastro-resistant tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 MYCLAUSEN Film-coated tablet MPI, EU: SmPC European Medicines Agency (EU)
 MYCOKEM 500 Film-coated tablet MPI, EU: SmPC Pharmaceutical Benefits Scheme (AU)
 MYFORTIC Gastro-resistant tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)

Medicines in this ATC group

United States (US)

Canada (CA)

France (FR)

Israel (IL)

Japan (JP)

Malta (MT)

Mexico (MX)

Netherlands (NL)

New Zealand (NZ)

Nigeria (NG)

Romania (RO)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.